收藏切换
Clinical trial design considerations for advanced therapy medicinal products in dystrophic epidermolysis bullosa
收藏切换
PDF
Chen-yang ZHAO, Shuang LU
Chinese Journal of Clinical Pharmacology | 2025, 41(22) : 3284 - 3289
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2025, 41(22): 3284-3289
Drug Evaluation and Administration
Clinical trial design considerations for advanced therapy medicinal products in dystrophic epidermolysis bullosa
Full
Chen-yang ZHAO, Shuang LU
Affiliations
  • Center for Drug Evaluation, National Medical Products Administration, Beijing 100076, China
Published: 2025-11-28 doi: 10.13699/j.cnki.1001-6821.2025.22.020
Outline
收藏切换

Dystrophic epidermolysis bullosa (DEB) is a mechanobullous disorder caused by mutations in the COL7A1 gene encoding type VII collagen. It has been included in China’s Rare Disease List, with clinical management primarily focused on preventing mechanical trauma and infections. In recent years, significant progress has been made in the development of advanced therapy medicinal products (ATMPs) for DEB, with two products already approved for marketing and multiple others undergoing clinical trials. This article reviews the fundamental characteristics of both approved and investigational ATMPs for DEB and discusses key considerations in clinical trial design, aiming to provide valuable insights for the clinical development of advanced therapies for this condition.

advanced therapeutic medicinal products  /  dystrophic epidermolysis bullosa  /  gene therapy  /  cell therapy  /  clinical trial design
Chen-yang ZHAO, Shuang LU. Clinical trial design considerations for advanced therapy medicinal products in dystrophic epidermolysis bullosa[J]. Chinese Journal of Clinical Pharmacology, 2025 , 41 (22) : 3284 -3289 . DOI: 10.13699/j.cnki.1001-6821.2025.22.020
Year 2025 volume 41 Issue 22
PDF
175
34
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2025.22.020
  • Receive Date:2025-09-15
  • Online Date:2026-08-05
  • Published:2025-11-28
Article Data
Affiliations
History
  • Received:2025-09-15
Funding
Affiliations
    Center for Drug Evaluation, National Medical Products Administration, Beijing 100076, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2025.22.020
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT